PL4045038T3 - Nowe preparaty 4-chloro-n-[2-[(4-chlorofenylo)metylo]-3-okso-1,2,4-tiadiazol-5-ilo]benzamidu - Google Patents

Nowe preparaty 4-chloro-n-[2-[(4-chlorofenylo)metylo]-3-okso-1,2,4-tiadiazol-5-ilo]benzamidu

Info

Publication number
PL4045038T3
PL4045038T3 PL20799795.8T PL20799795T PL4045038T3 PL 4045038 T3 PL4045038 T3 PL 4045038T3 PL 20799795 T PL20799795 T PL 20799795T PL 4045038 T3 PL4045038 T3 PL 4045038T3
Authority
PL
Poland
Prior art keywords
thiadiazol
benzamide
chlorophenyl
oxo
chloro
Prior art date
Application number
PL20799795.8T
Other languages
English (en)
Inventor
Thomas Edlund
Jacob Westman
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of PL4045038T3 publication Critical patent/PL4045038T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PL20799795.8T 2019-10-18 2020-10-16 Nowe preparaty 4-chloro-n-[2-[(4-chlorofenylo)metylo]-3-okso-1,2,4-tiadiazol-5-ilo]benzamidu PL4045038T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201915094A GB201915094D0 (en) 2019-10-18 2019-10-18 New formulations
PCT/GB2020/052618 WO2021074646A1 (en) 2019-10-18 2020-10-16 New formulations

Publications (1)

Publication Number Publication Date
PL4045038T3 true PL4045038T3 (pl) 2024-06-24

Family

ID=68728312

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20799795.8T PL4045038T3 (pl) 2019-10-18 2020-10-16 Nowe preparaty 4-chloro-n-[2-[(4-chlorofenylo)metylo]-3-okso-1,2,4-tiadiazol-5-ilo]benzamidu

Country Status (16)

Country Link
US (1) US20230096218A1 (pl)
EP (2) EP4045038B1 (pl)
JP (3) JP7554263B2 (pl)
KR (1) KR20220084379A (pl)
CN (2) CN119112886A (pl)
AU (1) AU2020366142A1 (pl)
CA (1) CA3154915A1 (pl)
DK (1) DK4045038T3 (pl)
ES (1) ES2977279T3 (pl)
FI (1) FI4045038T3 (pl)
GB (1) GB201915094D0 (pl)
HU (1) HUE066075T2 (pl)
MX (2) MX2022004615A (pl)
PL (1) PL4045038T3 (pl)
PT (1) PT4045038T (pl)
WO (1) WO2021074646A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
WO2025017193A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods of treating cardiomyopathy induced by metabolic inflexibility
WO2025017194A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (es) 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
WO2006045581A1 (en) 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
JP5982281B2 (ja) 2009-07-08 2016-08-31 バルティック バイオ アーベー 医薬として有用な化合物
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
AU2018448511B2 (en) * 2018-11-05 2025-07-03 Betagenon Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects

Also Published As

Publication number Publication date
CA3154915A1 (en) 2021-04-22
US20230096218A1 (en) 2023-03-30
HUE066075T2 (hu) 2024-07-28
EP4316470B1 (en) 2026-04-29
EP4045038A1 (en) 2022-08-24
JP7554263B2 (ja) 2024-09-19
CN114630824B (zh) 2024-09-24
EP4045038B1 (en) 2023-12-06
CN119112886A (zh) 2024-12-13
MX2025003950A (es) 2025-08-01
FI4045038T3 (fi) 2024-03-13
AU2020366142A1 (en) 2022-06-02
JP2022553268A (ja) 2022-12-22
WO2021074646A1 (en) 2021-04-22
MX2022004615A (es) 2022-07-11
JP2024174965A (ja) 2024-12-17
JP7771316B2 (ja) 2025-11-17
PT4045038T (pt) 2024-03-11
ES2977279T3 (es) 2024-08-21
CN114630824A (zh) 2022-06-14
GB201915094D0 (en) 2019-12-04
JP2026027357A (ja) 2026-02-18
KR20220084379A (ko) 2022-06-21
DK4045038T3 (en) 2024-03-18
EP4316470A3 (en) 2024-02-28
EP4316470A2 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
DK4045038T3 (en) New formulations of 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide
PH12020551304A1 (en) Novel crystalline forms
IL304392A (en) 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-4,2,1-thiadiazol-5-yl]benzamide for use in medicine
EP3735243A4 (en) ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE
IL284628A (en) Compositions of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile
MA56383A (fr) Analogues de3-(5-méthyl-1,3-thiazol-2-yl)-n-((1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl)benzamide
UY40935A (es) Composición tópica de hemihidrato de la base libre de n-[5(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]acetamida
IL289881A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide
EP3782212A4 (en) GENERATIVE MANUFACTURING USING ELECTROCHEMICALLY ACTIVE FORMULATIONS
EP3927868C0 (en) USE OF SULFIDIC COMPOSITIONS
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.
EP4021996A4 (en) Liquid electrophotographic ink compositions
IL276196B1 (en) Synthesis of 5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)thio]-thiazole
EA201891844A1 (ru) Продукт для ухода за полостью рта
EP3445763A4 (en) Novel Crystalline Salt Forms of 3- (1,2,4-triazolo [4,3-A] pyridine-3-yl-ethyl-2-yl) -4-methyl-N- (4 - ((4-methylpiperazine-1-yl) methyl) - 3-trifluoromethylphenyl) BENZAMIDE FOR MEDICAL USE
IL276227A (en) Crystal forms of the CXCR7 receptor antagonist (S4, S3)-1-cyclopropylmethyl-4-{[5-(4,2-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1 -pyrimidin-2-yl-cyclopropyl)-amide
IL288577A (en) Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
HK40103810A (en) 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine
IT201900022953A1 (it) “uso di una miscela pulente per la detersione di ugelli di stampanti digitali ceramiche”
GB201917723D0 (en) Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
EP4006125A4 (en) Additive composition
EP3958860A4 (en) COMPOUNDS WITH ANTI-TUBERCULOSIS ACTIVITY
EP4082627A4 (en) Composition for skin external application
PH12017500123B1 (en) Crystal of azole benzene derivative
HK40064245A (en) Use of 8,9-dihydrocannabidiol compounds